

261 Mountain View Dr  
Colchester, VT 05446  
License #: TLAB0030  
802-767-7256  
info@onwardanalytics.biz

# Certificate of Analysis



**Client Name:** Kria Commons

**License Number:** MANU-0005



**Sample ID:** VT12997

**Sample Name:** Hella Jelly Vape Blend


**Sample Lot:** MANU0005-24-BS-HJ1-V1

**Sample Matrix:** Solvent Extraction Concentrates

**Date Received:** 9/5/2024

**Date Reported:** 9/12/2024

**Date Tested:** 9/9/2024



**Total Terpenes (%) : 3.3959**

## Dominant Terpenes (%)

beta-caryophyllene	1.9439
alpha-Humulene	0.6126
Myrcene	0.4258
alpha-Bisabolol	0.1836
Limonene	0.1203

## Terpenes

Standard terpene analysis utilizing Gas Chromatography – Mass Spectrometry (GC-MS; SOP-069-OA) | Test ID: #39732

Analyte	Result (%)	Result (mg/g)	LOD (mg/g)	LOQ (mg/g)
3-Carene	ND	ND	0.000002	0.001
alpha-Bisabolol	0.1836	1.836	0.000003	0.001
alpha-Humulene	0.6126	6.126	0.000002	0.001
alpha-Pinene	0.0084	0.084	0.000001	0.001
alpha-Terpinene	ND	ND	0.000001	0.001
alpha-Terpinolene	ND	ND	0.000004	0.001
beta-caryophyllene	1.9439	19.439	0.000004	0.001
beta-Pinene	0.0175	0.175	0.000002	0.001
Camphene	< LOQ	< LOQ	0.000001	0.001
Caryophyllene Oxide	0.0493	0.493	0.000011	0.001
Eucalyptol	ND	ND	0.000002	0.001
gamma-Terpinene	ND	ND	0.000002	0.001
Geraniol	ND	ND	0.000008	0.003
Guaiol	ND	ND	0.000007	0.001
Isopulegol	ND	ND	0.000005	0.001
Isopropyl Toluene	ND	ND	0.000003	0.001
Limonene	0.1203	1.203	0.000002	0.001
Linalool	0.026	0.26	0.000003	0.001
Nerolidol	0.0085	0.085	0.000007	0.001
Myrcene	0.4258	4.258	0.000003	0.001
Ocimene	ND	ND	0.000002	0.001
<b>Total Terpenes</b>	<b>3.3959</b>	<b>33.959</b>		

*Callie Chapman*

Callie Chapman  
Lab Director  
9/12/2024

Rev. 1 Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

